Correlation of HER-2/neu Amplification With Expression and With Other Prognostic Factors in 1103 Breast Cancers

Ciocca, Daniel R.; Fujimura, Frank K.; Tandon, Atul K.; Clark, Gary M.; Mark, Corey; Lee-Chen, Guey Jen; Pounds, George; Vendely, Patricia; Owens, Marilyn A.; Pandian, M. R.; McGuire, William

doi:10.1093/jnci/84.16.1279

Cited by 87 publications

(56 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All tumors except one (Case 10) with HER2 gene amplification demonstrated overexpression of HER2 protein with the three antibodies used in this study. This outlying case may present a small-undetermined percentage that amplified HER2 without overexpression (6,16,20,26). The high rate of concordant results obtained by the two monoclonal antibodies was shown in this study.…”

Section: Discussionsupporting

confidence: 64%

Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma

Zhao

Wu²,

et al. 2002

Modern Pathology

149

110

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 64%

Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma

Zhao

Wu²,

et al. 2002

Modern Pathology

149

110

View full text Add to dashboard Cite

“…In our study antioncogene p53 overexpression was found in 31.4% of breast cancer cases. Antioncogene p53 was detected more often in premenopausal period (Table 3) which is consistent with literature data [13][14][15]. In postmenopausal patients, antioncogene p53 was found in 50% of cases (Table 3), which was higher than it is reported in world literature (25-30%).…”

Section: Discussionsupporting

confidence: 90%

Molecular markers (c-erbB-2, p53) in breast cancer.

Agrawal

Jeleń

Rudnicki³

et al. 2009

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

“…Parallel results were obtained in previous studies. The mechanism behind this negative correlation is ER and PR dependent down regulation of Her2/neu involve a complex molecular interaction as reported by Ciocca et al [19] and some vitro studies [20,21]. This may be one reason for Her2/neu over expressing women, resistant to tamoxifen.…”

Section: Discussionmentioning

confidence: 80%

Study of Hormone Receptors and Epidermal Growth Factor Expression in Invasive Breast Cancers in a Cohort of Western India

Dodiya¹,

Patel²,

Patel³

et al. 2013

Ind J Clin Biochem

View full text Add to dashboard Cite

The objective of study was to evaluate and correlate the pathological characteristics of breast cancer patients with estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2/neu) detected by immunohistochemistry and/or fluorescent in situ hybridization method. We have conducted 2 year study of 204 cases of breast cancer at HCG-Medisurge Hospitals, Ahmedabad from 2009 to 2011. Significant correlation was found in ER and PR expression whereas no correlation was found in hormonal receptors and Her2/neu expression. ER and PR positivity increased with advancing age in breast carcinoma patients while not affecting Her2/neu expression. The expression of hormone receptors were higher in infiltrating lobular carcinoma and infiltrating duct carcinoma subtypes of breast carcinoma as compared to other subtypes such medullary and in situ carcinoma. High-grade carcinoma patients were predominantly ER/PR negative and Her2/neu positive as compared to lower grade breast carcinoma whereas high-stage carcinoma patients were ER/PR positive and Her2/neu positive as compared to lower stage breast carcinoma.

show abstract

Correlation of HER-2/neu Amplification With Expression and With Other Prognostic Factors in 1103 Breast Cancers

Cited by 87 publications

References 0 publications

Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma

Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma

Molecular markers (c-erbB-2, p53) in breast cancer.

Study of Hormone Receptors and Epidermal Growth Factor Expression in Invasive Breast Cancers in a Cohort of Western India

Contact Info

Product

Resources

About